These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23561259)

  • 1. Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status.
    Tamai K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Katakami N; Tomii K
    Respir Investig; 2013 Mar; 51(1):46-8. PubMed ID: 23561259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
    Schwab R; Petak I; Kollar M; Pinter F; Varkondi E; Kohanka A; Barti-Juhasz H; Schönleber J; Brauswetter D; Kopper L; Urban L
    Lung Cancer; 2014 Jan; 83(1):109-11. PubMed ID: 24192513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.
    Li DL; Chen XR; Ma SX; Chen LK
    Thorac Cancer; 2016 Sep; 7(5):619-622. PubMed ID: 27766783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
    Toffart AC; Sakhri L; Moro-Sibilot D
    Rev Pneumol Clin; 2013 Apr; 69(2):111-6. PubMed ID: 23561899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
    Solomon B; Wilner KD; Shaw AT
    Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
    Gautschi O; Schefer H; Riklin C; Strobel K; Diebold J
    Onkologie; 2013; 36(6):342-7. PubMed ID: 23774148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Crystal AS; Shaw AT
    Clin Cancer Res; 2012 Sep; 18(17):4479-81. PubMed ID: 22912388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM; Bepler G
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
    Cao Y; Xiao G; Qiu X; Ye S; Lin T
    PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma.
    Kamide Y; Kaira K; Watanabe T; Kuribayashi S; Ozawa A; Koga Y; Ono A; Sunaga N; Hisada T; Oyama T; Yamada M
    Intern Med; 2015; 54(22):2905-9. PubMed ID: 26568007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.
    Jing X; Li F; Meng X; Liu Z; Yu J; Liu B
    Cancer Biol Ther; 2017 May; 18(5):279-284. PubMed ID: 28362192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
    Chiari R; Buttitta F; Iacono D; Bennati C; Metro G; Di Lorito A; Iezzi M; Tiseo M; Mazzoni F; Cappuzzo F; Marchetti A; Crinò L
    Clin Lung Cancer; 2014 Nov; 15(6):470-4. PubMed ID: 25087901
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for NSCLC: ALK inhibition.
    Pearson R; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.